Volume : 08, Issue : 05, May – 2021

Title:

34.PNEUMOCOCCAL CHEST INFECTION IN CHILDREN: A COMPREHENSIVE REVIEW

Authors :

Sabah Salik, Asma Anwar, Misbah Siddique

Abstract :

Childhood pneumococcal infection is a growing concern among pediatricians especially, in countries where there is no routine vaccination program against Streptococcal pneumonia. The disease is associated with significant morbidity and mortality in young children, particularly those who are under the age of two years. Its main virulent factors include polysaccharide capsules, autolysin, pneumolysin, choline-binding Protein A, the higher chance for genetic transformation, and the presence of pilli that facilitate enhanced binding of bacteria to host cellular surfaces. More severe and invasive pneumococcal infections are seen in children with immunodeficiencies, hypofunctional spleen, malnutrition, chronic lung disease, and nephrotic syndrome. The disease spectrum includes a range of manifestations from trivial upper respiratory tract infections to severe invasive pneumococcal disease (PD). The basis of diagnosis is the isolation of bacteria in the culture of body fluids, including blood. Sensitivity patterns best guide antibiotics, and the emergence of resistance is a growing concern.
Keyword: pneumonia, pneumococcal infection, children, streptococcal pneumonia

Cite This Article:

Please cite this article in press Sabah Salik et al., Pneumococcal Chest Infection In Children:
A Comprehensive Review.., Indo Am. J. P. Sci, 2021; 08(05).

Number of Downloads : 10

References:

1. WHO: Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec. Geneva: World Health Organization. 2007, 82:93-104.
2. Ryan KJ; Ray CG, eds: Sherris Medical Microbiology. McGraw Hill, New York; 2004.
3. Advisory Committee on Immunization Practices: Preventing pneumococcal diseases among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000, 49:1-35.
4. Hausdorff WP, Feikin DR, Klugman KP: Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005, 5:83-93.
5. Centers for Disease Control and Prevention (CDC): Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine – United States, 2007. MMWR Morb Mortal Wkly Rep. 2010, 59:253-7.
6. Brandileone MC, Vieira VS, Casagrande ST, et al.: Prevalence of serotypes and antimicrobial resistance of streptococcus pneumoniae strains isolated from Brazilian children with invasive infections. Pneumococcal Study Group in Brazil for the SIREVA Project. Regional System for Vaccines in Latin America. Microb Drug Resist. 1997, 3:141-6.
7. Hofmann J, Cetron MS, Farley MM, et al.: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995, 333:481-6.
8. Levine MM, Lagos R, Levine OS, et al.: Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr Infect Dis J. 1998, 17:287-93.
9. Butler JC, Breiman RF, Campbell JF, et al.: Pneumococcal polysaccharide vaccine efficacy. JAMA. 1993, 270:1826-31.
10. Duggan ST: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. Drugs. 2010, 70:1973-86.
11. Pineda SV, Perez BA, Domingo PM.: Bacteremic pneumococcal pneumonia. An Esp Pediatr. 2002, 57:408-13.
12. Brandenburg JA, Marrie TJ, Coley CM, Singer DE, Obrosky DS, Kapoor WN, Fine MJ: Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med. 2000, 15:638-46.
13. Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JI: Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis. 1996, 174:752-9.
14. Whitney CG, Farley MM, Hadler J, et al.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003, 348:1737-46.
15. Kaplan SL, Mason EO Jr, Wald ER, et al.: Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004, 113:443-9.
16. Pulido M, Sorvillo F: Declining invasive pneumococcal disease mortality in the United States, 1990-2005. Vaccine. 2010, 28:889-92.
17. Løchen A, Anderson RM: Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2020, 26:60-7.
18. Weiser JN, Ferreira DM, Paton JC: Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018, 16:355-67.
19. Hirst RA, Kadioglu A, O’callaghan C, Andrew PW: The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol. 2004, 138:195-201.
20. Pericone CD, Overweg K, Hermans PW, Weiser JN: Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun. 2000, 68:3990-7.
21. Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M: Interference between Streptococcus pneumoniae and Staphylococcus aureus: In vitro hydrogen peroxide-mediated killing by Streptococcus pneumoniae. J Bacteriol. 2006, 188:4996-5001.
22. Barocchi MA, Ries J, Zogaj X, et al.: A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A. 2006, 103:2857-62.
23. Siemieniuk RA, Gregson DB, Gill MJ: The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis. 2011, 11:314.
24. Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF, Moore MR: Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis. 2010, 50:175-83.
25. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000, 106:362-6.
26. Robinson KA, Baughman W, Rothrock G, et al.: Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA. 2001, 285:1729-35.
27. Marrie TJ: Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect. 1999, 14:227-36.
28. Peters BM, Jabra-Rizk MA, O’May GA, Costerton JW, Shirtliff ME: Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev. 2012, 25:193-21.
29. Anon JB: Treatment of acute bacterial rhinosinusitis caused by antimicrobial-resistant Streptococcus pneumoniae. Am J Med. 2004, 117:23S-8.
30. Priftis KN, Litt D, Manglani S, et al.: Bacterial bronchitis caused by Streptococcus pneumoniae and nontypable Haemophilus influenzae in children: the impact of vaccination. Chest. 2013, 143:152-7.
31. Schuchat A, Robinson K, Wenger JD, et al.: Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. 1997, 337:970-6.
32. Bacterial meningitis CDC. (2014). Accessed: 5 March 2016:
33. Rückinger S, von Kries R, Siedler A, van der Linden M: Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J. 2009, 28:118-22.
34. Davidson M, Schraer CD, Parkinson AJ, et al.: Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. JAMA . 1989, 261:715-8.
35. Joffe MD, Alpern ER: Occult pneumococcal bacteremia: a review. Pediatr Emerg Care. 2010, 26:448-54.
36. Kuppermann N, Fleisher GR, Jaffe DM: Predictors of occult pneumococcal bacteremia in young febrile children. Ann Emerg Med. 1998, 31:679-87.
37. Malley R, Ambrosino D : Pneumococcal diseases in children:morbidity, mortality, and resistance. Univ Chicago Child Hosp Rep Curr Concepts Use Pediatr Vaccines. 1998, 1:1-8.
38. Mufson MA : Pneumococcal infections. JAMA. 1981, 246:1942-8.
39. Hoare Z, Lim WS: Pneumonia: update on diagnosis and management. BMJ. 2006, 332:1077-9.
40. Weinberger DM, Harboe ZB, Sanders EA, et al.: Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis. 2010, 51:692-9.
41. Werno AM, Murdoch DR: Medical microbiology: laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis. 2008, 46:926-32.
42. Von Gottberg A, Klugman KP, Cohen C, et al.: Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. The Lancet. 2008, 371:1108-13.
43. Centers for Disease Control and Prevention: Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997, 46:1-24.
44. Rubin LG: Pneumococcal vaccine. Pediatr Clin North Am. 2000, 47:269-85.
45. Shapiro ED, Berg AT, Austrian R, et al.: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991, 325:1453-60.
46. Mangtani P, Cutts F, Hall AJ: Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003, 3:71-8.
47. O’Brien KL, Wolfson LJ, Watt JP, et al.: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009, 374:893-902.
48. Dinleyici EC, Yargic ZA: Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines. 2009, 8:977-86.
49. Prymula R, Hanovcova I, Splino M, et al.: Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. 2011.